Malaria (Plasmodium Falciparum)
10
4
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (10)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21
Malaria CVD 36000; Gates INV090205
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda
Artemisinin Partial Resistance in Ethiopian Plasmodium Falciparum: A Multisite Clinical, Molecular and In Vitro Study
Dose Finding Trial of R21/Matrix-M in School Children
Clinical Study of Meplazumab to Treat With Malaria